Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Veracyte (VCYT) over the last 14 years, with Q3 2025 value amounting to $68.3 million.

  • Veracyte's Operating Expenses rose 200.47% to $68.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $314.6 million, marking a year-over-year increase of 222.18%. This contributed to the annual value of $282.0 million for FY2024, which is 1061.12% down from last year.
  • Latest data reveals that Veracyte reported Operating Expenses of $68.3 million as of Q3 2025, which was up 200.47% from $95.0 million recorded in Q2 2025.
  • Veracyte's 5-year Operating Expenses high stood at $100.3 million for Q4 2023, and its period low was -$35.1 million during Q4 2022.
  • Its 5-year average for Operating Expenses is $73.0 million, with a median of $77.1 million in 2021.
  • As far as peak fluctuations go, Veracyte's Operating Expenses crashed by 14410.5% in 2022, and later surged by 38543.17% in 2023.
  • Veracyte's Operating Expenses (Quarter) stood at $79.7 million in 2021, then crashed by 144.1% to -$35.1 million in 2022, then soared by 385.43% to $100.3 million in 2023, then fell by 25.64% to $74.6 million in 2024, then fell by 8.37% to $68.3 million in 2025.
  • Its Operating Expenses stands at $68.3 million for Q3 2025, versus $95.0 million for Q2 2025 and $76.6 million for Q1 2025.